The North West of England Endocrinology, Diabetes and Obesity Newsletter

UK National Lipoprotein Apheresis Conference on 7th March 2014

Posted by Safwaan Adam on 16 January, 2014

2014 UK National Lipoprotein Apheresis Conference

7th March 2014, 09:00-1600


Venue: Hilton Manchester Airport Hotel,

Manchester Airport, Outwood Lane, Manchester,  M90 4WP

CPD accreditation: 5 CPD applied for


0920-0930  Welcome: Dr Handrean Soran

  Session 1

0930-1010  Underestimation of the importance of LDL-cholesterol lowering in   cardiovascular disease prevention in current practice. Professor Paul   Durrington, Professor of Medicine, University of Manchester, UK.

1010-1050  Lipoprotein (a) as a cardiovascular risk factor: review of evidence and   therapeutic options. Dr Dermot Neely, Consultant in Clinical Biochemistry   and Metabolic Medicine, Royal Victoria Infirmary, Newcastle, UK.

1050-1120   Coffee and networking

  Session 2

1120-1200  HoFH; is it just double trouble? The role of the LDL-receptor in lipid   metabolism and implications for therapeutic options. Dr Michael France,   Consultant Chemical Pathologist, Central Manchester University Hospitals   NHS Foundation Trust, Manchester, UK.

1200-1240  Lipoprotein Apheresis: who and how should we treat? Dr Dev Datta,   University Hospital Cardiff, Cardiff, UK.

1240-1350  Lunch

  Session 3

1350-1430  Lomitapide as a therapeutic option for HoFH. Professor Claudia Stefanutti,   Professor of Internal Medicine, Extracorporeal Therapeutic Techniques   Unit – Lipid Clinic and Atherosclerosis Prevention Centre, Department of   Molecular Medicine  ‘Sapienza’ University of Rome, Italy

1430-1500   Future therapeutic options for patients with HoFH.  Dr Handrean   Soran, Consultant Physician and Endocrinologist, Central Manchester   University Hospital, UK.

1500-1530  Managing HoFH in children; challenges and options. Dr Andrew Morris,   Consultant Paediatrician, Central Manchester University Hospitals NHS   Foundation Trust.

1530-1600  Case discussions.

HoFH in children; pheresis as a therapeutic option.

1600  Close


Aegereon, AMGEN, AstraZeneca, Link Medical, Sanofi.

Please download invite below:

Apheresis conference 2014 Manchester


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s